AMRX stock icon

Amneal Pharmaceuticals
AMRX

$7.43
4.47%

Market Cap: 2.29B

 

About: Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Employees: 7,700

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 5 analysts
0
News positive %
of 6 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

800% more call options, than puts

Call options by funds: $4.53M | Put options by funds: $503K

263% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 8

100% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 2 (+1) [Q1 2024]

38% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 48

14% more funds holding

Funds holding: 152 [Q4 2023] → 173 (+21) [Q1 2024]

4% less capital invested

Capital invested by funds: $677M [Q4 2023] → $651M (-$26.4M) [Q1 2024]

1.35% less ownership

Funds ownership: 36.4% [Q4 2023] → 35.05% (-1.35%) [Q1 2024]

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$6.25
16%
downside
Avg. target
$7.85
6%
upside
High target
$9
21%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
Goldman Sachs
Nathan Rich
8%upside
$8
Buy
Maintained
6 May 2024
Truist Securities
Les Sulewski
21%upside
$9
Buy
Reiterated
6 May 2024
Piper Sandler
David Amsellem
8%upside
$8
Overweight
Maintained
21 Mar 2024
Goldman Sachs
Nathan Rich
16%downside
$6.25
Buy
Maintained
4 Mar 2024
Barclays
Balaji Prasad
8%upside
$8
Overweight
Maintained
29 Jan 2024

Financial journalist opinion

Based on 6 articles about AMRX published over the past 30 days